What question did this study set out to answer?

To evaluate the effectiveness of the Chartis system in predicting significant lung volume reduction in heterogeneous emphysema patients after endobronchial valve therapy.

March 14, 2026

Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis

Key Points

To evaluate the effectiveness of the Chartis system in predicting significant lung volume reduction in heterogeneous emphysema patients after endobronchial valve therapy.
Enrolled patients with heterogeneous emphysema after HRCT assessment.
Utilized Chartis assessment to measure collateral resistance in the targeted lobe.
Treated all patients with Zephyr® endobronchial valves and measured primary and secondary endpoints.
Primary endpoint data collected for 24 patients; 75-80 total expected.
Average lung volume reduction observed in CV– patients is significantly higher than in CV+ patients.
Expanded patient selection criteria may allow broader eligibility for emphysema treatment.

Abstract

Introduction: Collateral ventilation (CV) has been shown to prevent lung volume reduction (LVR) after Endobronchial Valve (EBV) treatment. Direct measurement of CV may predict patients who will achieve significant LVR. The Chartis® Pulmonary Assessment System quantifies the average collateral resistance. When the resistance value >10, the patient is “CV Negative;” when the resistance value ≤10, the patient is “CV Negative;”. Objective: To evaluate the effectiveness of the Chartis® system in predicting subjects with heterogeneous emphysema who will achieve significant (≥350mL) LVR from EBV therapy. Methods: Patients with heterogenous emphysema were enrolled. Following Chartis assessment of the targeted lobe, that was determined by using HRCT, all patients were treated with Zephyr® EBV. Primary endpoint was HRCT-measured LVR in the treated lobe at 30-days. FEV 1 , SGRQ and 6MWT were evaluated as secondary endpoints. Results: To date, primary endpoint is collected for 24 patients. Primary and Secondary Endpoints for 75-80 patients are anticipated. Subgroup analyses will focus on patient selection criteria. Table 1 Average mL Volume Reduction (primary endpoint) Average Target Lobe Volume Reduction Average Heterogeneity Score Percentage of Upper Lobe Treatments FEV1 6-MWD SQRG CV+ (n=10) –90,5 –6,1% 24,1% 80% –3,1% 9,7% 0.7 (n=8) CV– (n=14) –1264.8 –79.0% 13.2% 50% 12.5% 9.0% –8.1(n=7) Δ 1174.3 72.9% 10,9% 16.0% 0,1% 7,4% Conclusion: Chartis System predicts significant LVR after EBV treatment. Results suggest that expanded patient selection criteria will enable successful treatment for a broader population of emphysema patients.

AI에게 질문

Bookmark